A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
A phase 3 trial testing Cetrelimab in bladder & urothelial cancer, active and no longer recruiting.
Overview
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) is a phase 3 interventional study registered as NCT05714202, led by Janssen Research & Development, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase 3, Open-Label, Multi-Center, Randomised Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer. Planned enrolment is 1135 participants (actual). The study started in 2023-03-23 and primary completion is expected in 2029-09-18. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Shares Cetrelimab, Johnson & Johnson, Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Shares Johnson & Johnson and the tag ctgov-ingest.
- TrialA Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.